Drug-resistant germs that defy the strongest medications cause more than 50,000 deaths annually in the United States, according to a sweeping federal health evaluation released on Oct. 27.
The Centers for Disease Control and Prevention issued its Antimicrobial Resistance Threats Report, tracking pathogens that pose a rising danger to patients. The agency has published the tracking report for the first time in seven years.
Channel 3000 reported that the federal assessment identifies 19 bacterial and fungal threats. These pathogens cause an estimated 9.7 million infections and 50,800 deaths each year nationwide.
Drug-resistant infections caught in healthcare environments account for more than 42,000 of those deaths. Those same hospital-acquired cases create more than $12 billion in annual costs.
These numbers are alarming by any measure but are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience,
Wendy S. Armstrong, president of the Infectious Diseases Society of America, said in a statement.
Armstrong explained that these infections prolong hospital stays and inflate healthcare costs. They also make it increasingly difficult, and sometimes impossible, for doctors to safely perform cancer chemotherapy, organ transplants, and joint replacements.
In Plain English: The Clinical Takeaway
- Superbugs: These are strains of bacteria or fungi that have mutated to become resistant to the standard antibiotics and medications normally used to destroy them.
- Healthcare-Acquired Infections: Germs picked up inside hospitals or nursing homes that strike vulnerable patients undergoing major surgeries or treatments.
- Antimicrobial Resistance: The biological process where microorganisms adapt to survive drug treatments, rendering standard medical therapies ineffective.
Four Pathogens Flagged as Urgent Threats
The federal report categorizes four specific pathogens as urgent threats, representing the most severe dangers to public health. These include Candida auris, Carbapenem-resistant Enterobacterales, Carbapenem-resistant Acinetobacter, and drug-resistant Neisseria gonorrhoeae.
Candida auris is a fungus that grows as a budding yeast and spreads primarily in healthcare settings through direct contact with infected individuals or contaminated surfaces. Healthy immune systems generally fight off the fungus, but immunocompromised patients face severe risks ranging from skin infections to life-threatening sepsis.
Case counts for Candida auris have climbed every year since 2019. The largest annual jump occurred between 2022 and 2023 with a 53.7% increase. As of Oct. 17, the United States logged 6,762 confirmed cases, surpassing the 6,560 cases reported during the entirety of the previous year.
Carbapenem-resistant Enterobacterales, often called nightmare bacteria, resist carbapenems, which are powerful broad-spectrum antibiotics. These bacteria live naturally in human and animal digestive tracts but cause dangerous infections when transmitted via contaminated hands, wounds, or medical devices.
An accompanying study highlighted a 69% increase in carbapenem-resistant infections between 2019 and 2023. That surge is tied to the NDM gene, which produces an enzyme that boosts antibiotic resistance. Researchers discovered a 460% increase in NDM-CRE infections during that same four-year window.
Environmental Spread and Sexual Transmission
Carbapenem-resistant Acinetobacter represents the third urgent threat on the federal list. This environmental bacterium lives on surfaces and human skin, causing infections in the lungs, urinary tract, wounds, and bloodstream.
Patients can carry and transmit Acinetobacter without showing any symptoms. It spreads rapidly through contaminated clinical equipment in hospitals and nursing homes.
Drug-resistant Neisseria gonorrhoeae causes gonorrhea. While total infections dropped over the past five years—with 543,409 confirmed cases recorded in 2024—widespread drug resistance persists due to the sheer volume of cases treated with antibiotics.
Untreated gonorrhea can lead to severe complications, including pelvic inflammatory disease, ectopic pregnancy, and infertility. The CDC notes that the nationwide count fell compared to the previous year, down from a peak of 710,151 infections in 2021.
| Pathogen Name | Classification | Primary Transmission Vector | Recent Epidemiological Trend |
|---|---|---|---|
| Candida auris | Urgent Fungal Threat | Healthcare settings, contaminated surfaces | 6,762 cases by mid-October, surpassing the prior year’s total |
| Carbapenem-resistant Enterobacterales | Urgent Bacterial Threat | Digestive tracts, clinical equipment, wounds | 69% increase in infections between 2019 and 2023 |
| Carbapenem-resistant Acinetobacter | Urgent Bacterial Threat | Environmental surfaces, skin, hospital gear | Persistent nosocomial transmission in long-term care |
| Drug-resistant Neisseria gonorrhoeae | Urgent Bacterial Threat | Sexual transmission | 543,409 cases in 2024, marking a decrease from 2023 |
Drivers of Resistance and Prevention Protocols
The overuse and misuse of antimicrobial drugs serve as primary drivers behind the rise of these resilient microorganisms. Improper medication use prompts bacteria and fungi to mutate and develop defense mechanisms against standard therapies.
Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year,
CDC Director Dr. Erica Schwartz said in a statement.
Practicing rigorous hygiene remains the most effective defense against contracting these pathogens. Thorough handwashing with soap and running water after using the bathroom, changing diapers, caring for sick individuals, handling food, or engaging in sexual activity helps prevent transmission.
Who Faces Infection Risks and When to Seek Medical Help
Patients with compromised immune systems, recent hospital stays, or indwelling medical devices face heightened susceptibility to opportunistic superbug infections. Individuals experiencing persistent fevers, non-healing surgical wounds, unexplained respiratory decline, or symptoms of a sexually transmitted infection should seek immediate professional medical evaluation.
Patients must never take leftover antibiotics or pressure clinicians to prescribe antimicrobial drugs for viral illnesses like the common cold or influenza, as unnecessary drug exposure accelerates microbial resistance.
References
- Centers for Disease Control and Prevention. Antimicrobial Resistance Threats Report.
- Infectious Diseases Society of America. Public Health Statements on Superbugs.
- Channel 3000. CDC identifies 4 drug-resistant germs that pose an ‘urgent threat’.
